SCHEMBL6981637

SCHEMBL6981637

CC1=CC(=O)CC(c2ccc(Cl)cc2)CN1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.58
ALDH1A1 P00352 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALOX12 P18054 1/20 0.58
HTT P42858 1/20 0.58
HSD17B10 Q99714 1/20 0.58
LMNA P02545 3/20 0.53
MAPK1 P28482 2/20 0.52
KDM4E B2RXH2 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
MAPT P10636 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
CYP2C19 P33261 1/20 0.52
KMT2A Q03164 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
L3MBTL1 Q9Y468 3/20 0.44
SLC6A3 Q01959 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22831445 0.76 TSHR (0.57) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL657357 0.76 TSHR (0.57) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL560686 0.76 TSHR (0.57) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL9669985 0.75 TSHR (0.55) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL6982349 0.74 POLB (0.46) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL31356811 0.73 POLB (1.00) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL20177951 0.69 HTR3A (0.47) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL6518239 0.67 SMN1; SMN2 (0.55) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL28640519 0.66 POLB (0.54) POLBALDH1A1SMN1; SMN2ALOX12HTT
SCHEMBL14544184 0.66 TSHR (0.61) ALDH1A1LMNAMAPK1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6451789-B1 CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS LES LABORTOIRES SERVIER (FR) 2002-09-17 US claimed
EP-1050530-B1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers SERVIER LAB (FR) 2003-10-22 EP disclosed
US-6451789-B1 CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS LES LABORTOIRES SERVIER (FR) 2002-09-17 US disclosed
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes RAULT SYLVAIN (FR) 2002-04-11 US disclosed
US-6323222-B1 COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS ADIR ET COMPAGNIE (FR) 2001-11-27 US disclosed
EP-1050530-A1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers ADIR ET COMPAGNIE (FR) 2000-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes SULT2A1, GRIN2A, NR3C1 POLB 2282/4885ALDH1A1 544/4885SMN1; SMN2 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.